{
 "id": "epkvhe76aw",
 "slug": "selex",
 "title": "SELEX",
 "updated": "2026-10-25",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.biology",
   "label": "Biological foundations",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology"
  },
  {
   "id": "life.biology.rna",
   "label": "RNA and gene regulation",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology.rna"
  },
  {
   "id": "life.biology.rna.rna-elements-and-technologies",
   "label": "RNA elements, catalytic RNAs, and technologies",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology.rna.rna-elements-and-technologies"
  },
  {
   "id": "life.biology.rna.rna-methods-resources",
   "label": "RNA methods, databases, and resources",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology.rna.rna-methods-resources"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t1946.life.biology.rna",
   "label": "Non-geographic · 1946 to 2000: RNA and gene regulation",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.biology.rna",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t1946",
     "label": "Non-geographic · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946"
    },
    {
     "id": "geo.nongeo.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life"
    },
    {
     "id": "geo.nongeo.t1946.life.biology",
     "label": "Biological foundations",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.biology"
    },
    {
     "id": "geo.nongeo.t1946.life.biology.rna",
     "label": "RNA and gene regulation",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.biology.rna"
    }
   ]
  }
 ],
 "excerpt": "SELEX (Systematic Evolution of Ligands by EXponential enrichment) is an in vitro selection method, reported in 1990, that isolates aptamers binding a chosen target molecule.",
 "snippet": "SELEX (Systematic Evolution of Ligands by EXponential enrichment) is an in vitro selection method, reported in 1990, that isolates aptamers binding a chosen target molecule.",
 "node": "life.biology.rna.rna-methods-resources",
 "markdown": "# SELEX\n\nSELEX (Systematic Evolution of Ligands by EXponential enrichment) is an in vitro selection method that iteratively enriches a random-sequence oligonucleotide pool to isolate aptamers, synthetic nucleic-acid receptors that bind a chosen target molecule.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup> An aptamer is a short RNA or DNA strand whose folded three-dimensional shape grips its target, a protein, small molecule, or whole cell.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup> Because aptamers are produced chemically rather than in animals, they serve as synthetic receptors in molecular diagnostics, synthetic biology, and therapeutics.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup>\n\n| Key fact | Detail |\n|---|---|\n| Product | Aptamers: folded ssDNA or RNA ligands to a target, found by iterative selection and amplification<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup> |\n| Starting pool | \\( 10^{14} \\)–\\( 10^{15} \\) unique sequences, with random regions<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup> |\n| Rounds | Typically 5–20; estimates range from 5–15 to more than 20 in conventional workflows<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup><sup> • </sup><sup>[4](https://doi.org/10.1038/mtna.2014.34)</sup> |\n| Enrichment per round | 10- to 1,000-fold in most platforms<sup>[4](https://doi.org/10.1038/mtna.2014.34)</sup> |\n| Library-to-target ratio | Suggested optimum 100:1 to 1000:1, with target concentration near the desired \\( K_{\\mathrm{d}} \\)<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup> |\n| Success rate | Estimated below 30% for a conventional campaign, improvable with specialized techniques<sup>[5](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)</sup> |\n| Approved drug | Macugen, approved in 2004 for macular degeneration<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup> |\n\n## How it works\n\nSELEX applies variation, selection, and replication, the mechanisms of Darwinian evolution, to a cell-free population of molecules.<sup>[6](https://doi.org/10.1126/science.2200121)</sup> A chemically synthesized library carries a central random region flanked by fixed primer-binding sites. Only a minute fraction of the molecules fold into shapes that bind the target; selection partitions these binders away from the rest, and PCR amplifies them; for RNA pools the selected RNA is first reverse-transcribed, and the resulting DNA is transcribed in vitro to regenerate the RNA pool. Repeating the cycle lets once-rare binders dominate: after 5–10 rounds the pool is dominated by target-binding molecules.<sup>[7](https://www.annualreviews.org/content/journals/10.1146/annurev.biochem.68.1.611)</sup> The exponential character comes from amplification: each round multiplies the survivors, so even sequences present at sub-parts-per-million frequency can be recovered.<sup>[8](https://www.jstage.jst.go.jp/article/analsci/37/1/37_20SAR18/_pdf)</sup>\n\n## How it is done\n\nOne round has four operations: binding, partitioning, amplification, and pool conditioning.<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup> A library of two ~20-base primer regions flanking a 20–60-base random region is incubated with the target, often immobilized on magnetic beads, nitrocellulose filters, or a column; bound sequences are separated and eluted, then amplified and regenerated as single strands.<sup>[8](https://www.jstage.jst.go.jp/article/analsci/37/1/37_20SAR18/_pdf)</sup> Counter-selection is not optional: a negative step against the bare matrix (beads, filter, or support) is needed to avoid enriching matrix-binding sequences, and counter-selection against similar molecules or tagged non-target proteins removes cross-reactive binders.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup> One consolidated strategy adds soluble off-targets during the washing stage, creating competitive binding without a separate negative round.<sup>[9](https://onlinelibrary.wiley.com/doi/10.1002/eng2.12089)</sup> Amplification must be restrained: 6–10 PCR cycles typically maximize correct double-stranded product before byproducts accumulate, and qPCR can reveal the minimal cycle number needed.<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup> Enrichment is monitored across rounds, with an enrichment value of 80% proposed as a stopping point; the final pool is cloned or sequenced, and candidate aptamers are synthesized and their \\( K_{\\mathrm{d}} \\) measured.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup><sup> • </sup><sup>[4](https://doi.org/10.1038/mtna.2014.34)</sup>\n\nRandom regions in practice run from 22 to 220 nt, averaging 30–80 nt, with 50–70 nt recommended as a compromise between diversity and handling.<sup>[5](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)</sup> [Mathematical analysis](https://www.edgepedia.org/mathematical-analysis) suggests 2–3 cycles would suffice under ideal partitioning, but non-ideal partitioning and PCR bias push practice to 5–15 rounds, with some reviews citing 8–20 cycles or more than 20 rounds.<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup><sup> • </sup><sup>[4](https://doi.org/10.1038/mtna.2014.34)</sup><sup> • </sup><sup>[10](https://pubs.rsc.org/nb/content/articlepdf/2025/lc/d4lc00859f?page=search)</sup> Enrichment of 10- to 1,000-fold per cycle means a minimum of three rounds even with high-throughput sequencing for a \\( 10^{16} \\)-complexity library.<sup>[4](https://doi.org/10.1038/mtna.2014.34)</sup> The overall success chance is estimated below 30%.<sup>[5](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)</sup>\n\n## Origin\n\nSELEX was reported in 1990 by two groups. Craig Tuerk and [Larry Gold](https://www.edgepedia.org/larry-gold) published \"Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase\" in Science, and [Andrew D. Ellington](https://www.edgepedia.org/andrew-d-ellington) and [Jack W. Szostak](https://www.edgepedia.org/jack-w-szostak) published \"In vitro selection of RNA molecules that bind specific ligands\" in Nature the same year.<sup>[6](https://doi.org/10.1126/science.2200121)</sup><sup> • </sup><sup>[11](https://doi.org/10.1038/346818a0)</sup> Tuerk named the process SELEX, while Ellington and Szostak named the resulting molecules aptamers, from Latin aptus (to fit) and Greek meros (particle).<sup>[12](https://link.springer.com/article/10.1007/s00239-015-9705-9)</sup><sup> • </sup><sup>[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC3257122/)</sup> The method built on earlier work: Arnold R. Oliphant, Christopher J. Brandl, and Kevin Struhl selected DNA-binding sites for yeast GCN4 from random-sequence oligonucleotides in 1989, but without rounds of amplification; PCR made iterating the procedure sensible.<sup>[14](https://doi.org/10.1128/mcb.9.7.2944-2949.1989)</sup><sup> • </sup><sup>[12](https://link.springer.com/article/10.1007/s00239-015-9705-9)</sup> Sol Spiegelman's 1960s Qβ replicase experiments had already shown Darwinian selection operating in a cell-free system, selecting for replication speed.<sup>[7](https://www.annualreviews.org/content/journals/10.1146/annurev.biochem.68.1.611)</sup> Gold's group founded NeXagen in 1992, which became NeXstar and was sold to Gilead in mid-1999.<sup>[12](https://link.springer.com/article/10.1007/s00239-015-9705-9)</sup>\n\n## Variants\n\nVariants change how the target is presented or how partitioning is done. Magnetic-bead formats allow coupling of small molecules that filters cannot retain; FluMag-SELEX, reported by R. Stoltenburg, C. Reinemann, and B. Strehlitz in 2005, adds fluorescently labeled primers to a bead-based DNA selection.<sup>[15](https://doi.org/10.1007/s00216-005-3388-9)</sup> Cell-SELEX, introduced by Dihua Shangguan and colleagues in 2006, evolves aptamers against live cells, so targets remain in their native membrane context; it typically needs 10–30 rounds.<sup>[16](https://doi.org/10.1073/pnas.0602615103)</sup><sup> • </sup><sup>[8](https://www.jstage.jst.go.jp/article/analsci/37/1/37_20SAR18/_pdf)</sup> CE-SELEX, reported by Shaun D. Mendonsa and Michael T. Bowser in 2003, uses capillary electrophoresis to partition binders in free solution, cutting rounds to 1–4.<sup>[17](https://doi.org/10.1021/ja037832s)</sup><sup> • </sup><sup>[18](https://www.mdpi.com/1422-0067/18/10/2142)</sup> The related non-SELEX workflow repeats capillary partitioning without PCR and can yield aptamers after a single cycle when partition efficiency exceeds \\( 10^{6} \\)–\\( 10^{7} \\).<sup>[8](https://www.jstage.jst.go.jp/article/analsci/37/1/37_20SAR18/_pdf)</sup> Spiegelmer technology selects a natural D-oligonucleotide pool against a mirror-image (D-enantiomer) target and then synthesizes the corresponding L-oligonucleotide aptamer, whose non-natural L-sugars resist nuclease cleavage; it requires access to a mirror-image form of the target. Click-SELEX, reported by Franziska Pfeiffer and colleagues in 2018, identifies nucleobase-modified aptamers with expanded chemical functionality.<sup>[19](https://doi.org/10.1038/nprot.2018.023)</sup>\n\n## Applications\n\nAptamers from SELEX work as therapeutics, diagnostic reagents, and biosensor recognition elements.<sup>[1](https://www.nature.com/articles/s43586-023-00238-7)</sup> Macugen (pegaptanib), the first VEGF antagonist approved for age-related macular degeneration, came out of the NeXstar program and was approved in 2004.<sup>[12](https://link.springer.com/article/10.1007/s00239-015-9705-9)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup> SOMAmer reagents (Slow Off-rate Modified Aptamers), which carry adducts at the five position of cytosine and thymine accepted by many DNA polymerases, were originally developed by [SomaLogic](https://www.edgepedia.org/somalogic) and power the multiplex SomaScan proteomic assay; SomaLogic was acquired by Illumina from Standard BioTools in a sale completed January 30, 2026.<sup>[12](https://link.springer.com/article/10.1007/s00239-015-9705-9)</sup> In biosensors and separations, aptamers serve as replaceable, chemically produced recognition layers.<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup>\n\n## Limitations and alternatives\n\nPCR bias is a central failure mode: GC- and AT-rich and highly structured sequences amplify poorly, shorter fragments amplify better, and pushing many cycles to enrich binders can lower the success chance; emulsion PCR reduces bias and preserves rare binders.<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup><sup> • </sup><sup>[5](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)</sup> Selection can also enrich sequences that bind protein tags (His-tag, biotin), or the solid support rather than the target, and aptamers raised against recombinant protein may fail to recognize the native target on a cell surface because of tags, linkers, glycosylation, or misfolding.<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup><sup> • </sup><sup>[20](https://pmc.ncbi.nlm.nih.gov/articles/PMC7321788/)</sup> Even high-affinity cell-SELEX aptamers have later failed in vivo, and 20–70-nt aptamers are rapidly cleared by kidney filtration.<sup>[20](https://pmc.ncbi.nlm.nih.gov/articles/PMC7321788/)</sup><sup> • </sup><sup>[18](https://www.mdpi.com/1422-0067/18/10/2142)</sup> Several recent publications reported that some published aptamer sequences do not bind their targets as originally claimed, prompting proposed minimum publication standards from the Aptamer Consortium.<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)</sup> Compared with antibodies, aptamers are produced in vitro and chemically, but few have reached commercial use against the mature antibody market.<sup>[18](https://www.mdpi.com/1422-0067/18/10/2142)</sup>\n\nSince 2023 the main changes are sequencing-integrated analysis, automation, and machine learning. [High-throughput sequencing](https://www.edgepedia.org/high-throughput-sequencing) can detect binders within 2–3 cycles by enrichment-rate scoring and identify candidates between rounds two and four,<sup>[3](https://www.mdpi.com/1420-3049/24/19/3598)</sup><sup> • </sup><sup>[5](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)</sup> with Hoinka, Backofen, and Przytycka's AptaSUITE providing a dedicated bioinformatics framework for HT-SELEX data.<sup>[21](https://doi.org/10.1016/j.omtn.2018.04.006)</sup> Auto-SELEX, a fully automated microfluidic platform, completes each round in about 30 minutes and yielded DNA aptamers against human IgE and vitronectin in two to three rounds, with \\( K_{\\mathrm{d}} \\) below 20 nM and 100 nM respectively.<sup>[22](https://pubs.rsc.org/en/content/articlehtml/2026/lc/d6lc00275g)</sup> AptaDiff, reported by Zhen Wang and colleagues in 2024, applies diffusion models to de novo aptamer design.<sup>[23](https://doi.org/10.1093/bib/bbae517)</sup> [Skepticism](https://www.edgepedia.org/skepticism) persists, however: limited structural data, difficulty predicting non-canonical pairs and pseudoknots, and poor generalizability of machine-learning models to new sequence families temper expectations for purely computational design.<sup>[24](https://journals.rcsi.science/0026-8984/article/view/446136)</sup>\n\n## References\n\n1. [In vitro selection of aptamers and their applications | Nature Reviews Methods Primers](https://www.nature.com/articles/s43586-023-00238-7)\n2. [Aptamers 101: aptamer discovery and in vitro applications in biosensors and separations (Chemical Science, RSC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10189874/)\n3. [Inside the Black Box: What Makes SELEX Better? (Biomolecules, MDPI; same paper also mirrored at PMC6804172)](https://www.mdpi.com/1420-3049/24/19/3598)\n4. [New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization (Molecular Therapy - Nucleic Acids, 2014)](https://doi.org/10.1038/mtna.2014.34)\n5. [SELEX: Critical factors and optimization strategies for successful aptamer selection (Kohlberger & Gadermaier, Biotechnology and Applied Biochemistry)](https://obgyn.onlinelibrary.wiley.com/doi/10.1002/bab.2244)\n6. [Craig Tuerk, Larry Gold (1990). Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase. Science.](https://doi.org/10.1126/science.2200121)\n7. [In Vitro Selection of Functional Nucleic Acids (Annual Review of Biochemistry, 1999)](https://www.annualreviews.org/content/journals/10.1146/annurev.biochem.68.1.611)\n8. [SELEX-based DNA Aptamer Selection: A Perspective from the Advancement of Separation Techniques (Analytical Sciences)](https://www.jstage.jst.go.jp/article/analsci/37/1/37_20SAR18/_pdf)\n9. [A systematic evolution of ligands by exponential enrichment workflow with consolidated counterselection to efficiently isolate high-affinity aptamers (Engineering Reports)](https://onlinelibrary.wiley.com/doi/10.1002/eng2.12089)\n10. [Microfluidic SELEX review (Lab on a Chip, RSC, 2025)](https://pubs.rsc.org/nb/content/articlepdf/2025/lc/d4lc00859f?page=search)\n11. [Andrew D. Ellington, Jack W. Szostak (1990). In vitro selection of RNA molecules that bind specific ligands. Nature.](https://doi.org/10.1038/346818a0)\n12. [SELEX: How It Happened and Where It will Go (Journal of Molecular Evolution, 2015)](https://link.springer.com/article/10.1007/s00239-015-9705-9)\n13. [RNA Aptamer Evolution: Two Decades of SELEction](https://pmc.ncbi.nlm.nih.gov/articles/PMC3257122/)\n14. [Arnold R. Oliphant, Christopher J. Brandl, Kevin Struhl (1989). Defining the Sequence Specificity of DNA-Binding Proteins by Selecting Binding Sites from Random-Sequence Oligonucleotides: Analysis of Yeast GCN4 Protein. Molecular and Cellular Biology.](https://doi.org/10.1128/mcb.9.7.2944-2949.1989)\n15. [R. Stoltenburg, C. Reinemann, B. Strehlitz (2005). FluMag-SELEX as an advantageous method for DNA aptamer selection. Analytical and Bioanalytical Chemistry.](https://doi.org/10.1007/s00216-005-3388-9)\n16. [Dihua Shangguan and colleagues (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proceedings of the National Academy of Sciences.](https://doi.org/10.1073/pnas.0602615103)\n17. [Shaun D. Mendonsa, Michael T. Bowser (2003). In Vitro Evolution of Functional DNA Using Capillary Electrophoresis. Journal of the American Chemical Society.](https://doi.org/10.1021/ja037832s)\n18. [Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine (Int. J. Mol. Sci., 2017)](https://www.mdpi.com/1422-0067/18/10/2142)\n19. [Franziska Pfeiffer and colleagues (2018). Identification and characterization of nucleobase-modified aptamers by click-SELEX. Nature Protocols.](https://doi.org/10.1038/nprot.2018.023)\n20. [Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?](https://pmc.ncbi.nlm.nih.gov/articles/PMC7321788/)\n21. [Jan Hoinka, Rolf Backofen, Teresa M. Przytycka (2018). AptaSUITE: A Full-Featured Bioinformatics Framework for the Comprehensive Analysis of Aptamers from HT-SELEX Experiments. Molecular Therapy, Nucleic Acids.](https://doi.org/10.1016/j.omtn.2018.04.006)\n22. [Auto-SELEX: a fully automated microfluidic platform for rapid discovery of high-affinity aptamers (Lab on a Chip, RSC)](https://pubs.rsc.org/en/content/articlehtml/2026/lc/d6lc00275g)\n23. [Zhen Wang and colleagues (2024). AptaDiff: de novo design and optimization of aptamers based on diffusion models. Briefings in Bioinformatics.](https://doi.org/10.1093/bib/bbae517)\n24. [Modern methods of molecular modeling of aptamers (Kudryashova, Molecular Biology)](https://journals.rcsi.science/0026-8984/article/view/446136)\n\n---\n*Topic: Encyclopedia › Life and health › Biological foundations › RNA and gene regulation › RNA elements, catalytic RNAs, and technologies › RNA methods, databases, and resources*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026; Oct 25, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/selex",
 "markdown_url": "https://www.edgepedia.org/selex.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"SELEX\", Edgepedia (EdgeChat), https://www.edgepedia.org/selex. Edgepedia Community License 1.0.",
 "credit_md": "\"[SELEX](https://www.edgepedia.org/selex)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/selex](https://www.edgepedia.org/selex). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/selex\">SELEX</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/selex\">https://www.edgepedia.org/selex</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "SELEX is an in vitro selection method, reported in 1990, that isolates aptamers binding a chosen target molecule."
}